Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Sniderman, S. Tsimikas, S. Fazio (2014)
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.Journal of the American College of Cardiology, 63 19
E. Stein, M. Koren, Narimon Honarpour, C. Kurtz, Jingyuan Yang, S. Wasserman, F. Raal (2015)
CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIESJournal of the American College of Cardiology, 65
R. Santos, G. Watts (2015)
Familial hypercholesterolaemia: PCSK9 inhibitors are comingThe Lancet, 385
Jennifer Robinson, B. Nedergaard, W. Rogers, J. Fialkow, J. Neutel, David Ramstad, R. Somaratne, J. Legg, Patric Nelson, R. Scott, S. Wasserman, R. Weiss (2014)
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.JAMA, 311 18
D. Blom, T. Hála, M. Bolognese, M. Lillestol, P. Toth, L. Burgess, R. Češka, E. Roth, M. Koren, C. Ballantyne, M. Monsalvo, Kate Tsirtsonis, Jae Kim, R. Scott, S. Wasserman, E. Stein (2014)
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.The New England journal of medicine, 370 19
G Villa, T Schmid, M Lothgren (2014)
LDL-C lowering efficacy of evolocumab (AMG 145) could reduce apheresis in patients at high risk for cardiovascular events in Germany [abstract no. PCV183]Value Health., 17
Jennifer Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, E. Stroes, G. Langslet, F. Raal, M. Shahawy, M. Koren, N. Lepor, C. Lorenzato, R. Pordy, U. Chaudhari, J. Kastelein (2015)
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.The New England journal of medicine, 372 16
D. Blom, C. Djedjos, M. Monsalvo, I. Bridges, S. Wasserman, R. Scott, E. Roth (2015)
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.Circulation Research
D. Sullivan, A. Olsson, R. Scott, Jae Kim, Allen Xue, V. Gebski, S. Wasserman, E. Stein (2012)
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.JAMA, 308 23
M. Koren, R. Scott, Jae Kim, B. Knusel, Thomas Liu, Lei Lei, M. Bolognese, S. Wasserman (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet, 380
A. Markham (2015)
Alirocumab: First Global ApprovalDrugs, 75
J. Levy, P. Verhamme, F. Sellke, P. Reilly, R. Dubiel, J. Eikelboom, E. Hylek, J. Kreuzer, J. Weitz, C. Pollack (2015)
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD studyEuropean Heart Journal, 36
N. Seidah, Z. Awan, M. Chrétien, M. Mbikay (2014)
PCSK9: A Key Modulator of Cardiovascular HealthCirculation Research, 114
M. Sabatine, R. Giugliano, S. Wiviott, F. Raal, D. Blom, Jennifer Robinson, C. Ballantyne, R. Somaratne, J. Legg, S. Wasserman, R. Scott, M. Koren, E. Stein (2015)
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.The New England journal of medicine, 372 16
(2015)
Pfizer launches first annual PCSK9 competitive grants program to advance cardiovascular disease research
M. Koren, D. Blom, R. Giugliano, E. Stroes, R. Somaratne, A. Lowy, M. Monsalvo, Hui-Chun Hsu, S. Wasserman, R. Scott, Sabatine (2014)
Abstract 16865: Safety and Tolerability of Very Low LDL-C Levels in Patients Treated with 52 Weeks of Evolocumab (AMG 145)Circulation, 130
M. Koren, R. Giugliano, F. Raal, D. Sullivan, M. Bolognese, G. Langslet, F. Civeira, A. Lowy, R. Somaratne, Thomas Liu, S. Wasserman, R. Scott, M. Sabatine (2015)
TWO YEAR ANALYSIS OF THE SAFETY AND TOLERABILITY OF EVOLOCUMAB: THE OSLER-1 STUDYJournal of the American College of Cardiology, 65
(2015)
Long-term safety and efficacy of evolocumab in patients with statin intolerance [abstract no. P5968
R. Giugliano, N. Desai, P. Kohli, W. Rogers, R. Somaratne, Fannie Huang, Thomas Liu, Satishkumar Mohanavelu, Elaine Hoffman, S. McDonald, Timothy Abrahamsen, S. Wasserman, R. Scott, M. Sabatine (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet, 380
F Raal, R Scott, R Somaratne (2012)
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trialCirculation., 126
M. Koren, Pernille Lundqvist, M. Bolognese, J. Neutel, M. Monsalvo, Jingyuan Yang, Jae Kim, R. Scott, S. Wasserman, H. Bays (2014)
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.Journal of the American College of Cardiology, 63 23
J. Gibbs, A. Grover, M. Emery, Michael Dodds, R. Somaratne, S. Wasserman (2015)
Impact of target-mediated elimination on evolocumab dose and regimenAtherosclerosis, 241
(2015)
Repatha (evolocumab) solution for subcutaneous injection: Canadian product monograph
Rachna Seth, S. Gulati, Sandeep Seth, P. Menon, Veena Kalra (2004)
Familial hypercholesterolemiaThe Indian Journal of Pediatrics, 71
M. Koren, R. Giugliano, F. Raal, D. Sullivan, M. Bolognese, G. Langslet, F. Civeira, R. Somaratne, Patric Nelson, Thomas Liu, R. Scott, S. Wasserman, M. Sabatine (2014)
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized TrialCirculation, 129
G. Watts, S. Gidding, A. Wierzbicki, P. Toth, P. Toth, R. Alonso, W. Brown, E. Bruckert, J. Defesche, Khoo Lin, M. Livingston, P. Mata, K. Parhofer, F. Raal, R. Santos, E. Sijbrands, W. Simpson, D. Sullivan, A. Susekov, B. Tomlinson, A. Wiegman, S. Yamashita, J. Kastelein (2014)
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation.Journal of clinical lipidology, 8 2
G. Villa, T. Schmid, M. Lothgren, G. Michailov (2014)
Ldl-C Lowering Efficacy of Evolocumab (Amg 145) Could Reduce Apheresis in Patients At High Risk for Cardiovascular Events in Germany.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
F. Raal, Evan Stein, R. Dufour, T. Turner, F. Civeira, L. Burgess, G. Langslet, Russell Scott, Anders Olsson, D. Sullivan, G. Hovingh, B. Cariou, I. Gouni-Berthold, R. Somaratne, Ian Bridges, R. Scott, S. Wasserman, D. Gaudet (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 385
N. Stone, Jennifer Robinson, A. Lichtenstein, C. Noel, B. Merz, D. Lloyd‐Jones, C. Blum, P. Mcbride, R. Eckel, F. Schwartz, A. Goldberg, Susan Shero, Rn, D. Gordon, Sidney Smith, D. Levy, K. Watson, P. Wilson, Karen Eddleman, N. Jarrett, K. Labresh, Lev Nevo, J. Wnek, Jeffrey Anderson, J. Halperin, N. Albert, J. Hochman, B. Bozkurt, R. Kovacs, R. Brindis, Macc Ohman, L. Curtis, S. Pressler, D. DeMets, F. Sellke, R. Guyton, W. Shen, G. Tomaselli, Stone Nj, Robinson J, Lichtenstein Ah, M. Bairey, Blum Cn, Eckel Cb, Goldberg Rh, Gordon Ac, Levy D, Lloyd-Jones Dm, P. Mcbride, Js Schwartz, Shero St, Smith Sc, W. Wilson (2014)
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation, 129 25 Suppl 2
F. Raal, Narimon Honarpour, D. Blom, G. Hovingh, Feng Xu, R. Scott, S. Wasserman, E. Stein (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialThe Lancet, 385
SM Wasserman, MJ Koren, RP Giugliano (2014)
Evaluation of the relationship between evolocumab 140 mg every two weeks and 420 mg monthly dosing regimensCirculation., 130
(2015)
Relationship of body weight and dosing of evolocumab (EVO) for the treatment of hypercholesterolemia [abstract no. P5984
PP Toth, N Sattar, J Genest (2015)
A comprehensive safety analysis of 6026 patients from phase 2 and 3 short and long term clinical trials with evolocumab (AMG 145) [abstract no. 1164 M-07 plus poster]J Am Coll Cardiol., 65
EA Stein, SM Wasserman, C Dias (2013)
AMG-145Drugs Future., 48
C. Dias, A. Shaywitz, S. Wasserman, Brian Smith, Bing Gao, Dina Stolman, C. Crispino, K. Smirnakis, M. Emery, A. Colbert, J. Gibbs, M. Retter, Blaire Cooke, Stephen Uy, M. Matson, E. Stein (2012)
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.Journal of the American College of Cardiology, 60 19
B. Nordestgaard, M. Chapman, K. Ray, J. Borén, F. Andreotti, G. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. Descamps, E. Fisher, P. Kovanen, J. Kuivenhoven, P. Lesnik, L. Masana, Ž. Reiner, M. Taskinen, L. Tokgözoğlu, A. Tybjærg‐Hansen (2010)
Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 31
A. Kiyosue, Narimon Honarpour, Allen Xue, S. Wasserman, A. Hirayama (2015)
EFFECTS OF EVOLOCUMAB (AMG 145) IN HYPERCHOLESTEROLEMIC, STATIN-TREATED, JAPANESE PATIENTS AT HIGH CARDIOVASCULAR RISK: RESULTS FROM THE PHASE III YUKAWA 2 STUDYJournal of the American College of Cardiology, 65
Xin-lin Zhang, Qingqing Zhu, Li Zhu, Jian-Zhou Chen, Qinhua Chen, Guannan Li, Jun Xie, L. Kang, Biao Xu (2015)
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsBMC Medicine, 13
A. Hirayama, Narimon Honarpour, M. Yoshida, S. Yamashita, Fannie Huang, S. Wasserman, T. Teramoto (2014)
Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.Circulation journal : official journal of the Japanese Circulation Society, 78 5
E Stroes, J Robinson, F Raal (2015)
Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies [abstract no. P1756 plus poster]Eur Heart J., 36
F. Raal, R. Giugliano, M. Sabatine, M. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. Wasserman, Fannie Huang, Allen Xue, Moetaz Albizem, R. Scott, E. Stein (2014)
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.Journal of the American College of Cardiology, 63 13
F. Raal, R. Scott, R. Somaratne, I. Bridges, Gang Li, S. Wasserman, E. Stein (2012)
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial HypercholesteroleCirculation, 126
E. Stroes, Jennifer Robinson, F. Raal, R. Dufour, D. Sullivan, M. Blagden, H. Kassahun, Jingyuan Yang, S. Wasserman, M. Koren (2015)
CLINICAL EQUIVALENCE OF EVOLOCUMAB AMONG PATIENT SUBGROUPS IN PROFICIO: A POOLED ANALYSIS OF 3146 PATIENTS FROM PHASE 3 STUDIESCanadian Journal of Cardiology, 31
D. Karasoy, G. Gislason, J. Hansen, A. Johannessen, L. Køber, M. Hvidtfeldt, Cengiz Özcan, C. Torp-Pedersen, M. Hansen (2015)
Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark.European heart journal, 36 5
A. Catapano, Željko Reiner, G. Backer, I. Graham, M. Taskinen, O. Wiklund, S. Agewall, E. Alegrı́a, M. Chapman, P. Durrington, S. Erdine, J. Halcox, Richard Hobbs, J. Kjekshus, P. Filardi, G. Riccardi, R. Storey, D. Wood, P. Kolh (2011)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).European heart journal, 32 14
(2015)
Evolocumab pharmacokinetics and its effects on LDL-C and PCSK9 lowering in subjects with mild or moderate hepatic impairment [abstract no. PII-034
M. Page, G. Watts (2015)
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacologyExpert Opinion on Drug Metabolism & Toxicology, 11
E. Stein, Narimon Honarpour, S. Wasserman, Feng Xu, R. Scott, F. Raal (2013)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial HypercholesterolemiaCirculation, 128
H. Iso, D. Jacobs, D. Wentworth, J. Neaton, J. Cohen (1989)
Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.The New England journal of medicine, 320 14
P. Toth, N. Sattar, J. Genest, O. Descamps, R. Dent, C. Djedjos, J. Legg, S. Wasserman, E. Stein (2015)
A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145)Journal of the American College of Cardiology, 65
(2016)
'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias.European heart journal, 37 39
A. Catapano, Željko Reiner, G. Backer, I. Graham, M. Taskinen, O. Wiklund, S. Agewall, Eduardo Alegría, M. Chapman, P. Durrington, S. Erdine, J. Halcox, Richard Hobbs, J. Kjekshus, P. Filardi, G. Riccardi, R. Storey, D. Wood (2011)
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis, 217 1
A Kiyosue, N Honarpour, A Xue (2015)
Effects of evolocumab (AMG 145) in hypercholesterolemic, statin-treated, Japanese patients at high cardiovascular risk: results from the phase III YUKAWA 2 study [abstract no. 1107-104 plus poster]J Am Coll Cardiol., 65
J. Provencio (2007)
High-Dose Atorvastatin after Stroke or Transient Ischemic AttackYearbook of Critical Care Medicine, 2007
JL Goldstein, HH Hobbs, MS Brown (2001)
The Metabolic and Molecular Bases of Inherited Disease
M. Koren, R. Rosenson, B. Khan, Narimon Honarpour, M. Elliott, R. Somaratne, S. Wasserman, E. Stroes (2015)
LDL CHOLESTEROL REDUCTION IN ELDERLY PATIENTS WITH THE PCSK9 MONOCLONAL ANTIBODY EVOLOCUMAB (AMG 145): A POOLED ANALYSIS OF 1779 PATIENTS IN PHASE 2, 3 AND OPEN LABEL EXTENSION STUDIESJournal of the American College of Cardiology, 65
P Amarenco, J Bogousslavsky, A Callahan (2006)
High-dose atorvastatin after stroke or transient ischemic attackN Engl J Med., 355
S. Wasserman, M. Koren, R. Giugliano, J. Gibbs, J. Legg, M. Emery, P. Haughney, Thomas Liu, R. Scott, M. Sabatine (2014)
Abstract 16270: Evaluation of the Relationship Between Evolocumab 140 mg Every Two Weeks and 420 mg Monthly Dosing RegimensCirculation, 130
E. Navarese, M. Kołodziejczak, V. Schulze, P. Gurbel, U. Tantry, Yingfeng Lin, M. Brockmeyer, D. Kandzari, J. Kubica, R. D'Agostino, J. Kubica, M. Volpe, S. Agewall, D. Kereiakes, M. Kelm (2015)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.Annals of internal medicine, 163 1
Rocco Romagnuolo, Corey Scipione, M. Boffa, S. Marcovina, N. Seidah, M. Koschinsky (2015)
Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor*The Journal of Biological Chemistry, 290
E. Stroes, D. Colquhoun, D. Sullivan, F. Civeira, R. Rosenson, G. Watts, E. Bruckert, L. Cho, R. Dent, B. Knusel, Allen Xue, R. Scott, S. Wasserman, Michael Rocco (2014)
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.Journal of the American College of Cardiology, 63 23
F. Raal, C. Kurtz, Narimon Honarpour, Lihua Tang, E. Stein (2016)
Cardiovascular event rates in homozygous familial hypercholesterolemia (HoFH): Trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG) study interim resultsAtherosclerosis, 252
MJ Koren, D Blom, RP Giugliano (2014)
Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145)Circulation., 130
Evolocumab (Repatha®) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg every 2 weeks or 420 mg once monthly. Across 12-week phase III trials in patients with primary hypercholesterolemia or mixed dyslipidemia, evolocumab was more effective than placebo (treatment difference −54.8 to −76.3 %) and/or ezetimibe (treatment difference −36.9 to −47.2 %) at reducing low-density lipoprotein cholesterol (LDL-C) levels, including when added to statin therapy, when administered to statin-intolerant patients, when administered as monotherapy, and in patients with heterozygous familial hypercholesterolemia who were receiving statins with or without other lipid-lowering drugs. Evolocumab also significantly lowered LDL-C levels (treatment difference of ≈30 % vs. placebo) in patients with homozygous familial hypercholesterolemia when added to statins with or without ezetimibe in a 12-week phase III trial. The efficacy of evolocumab was maintained in the longer term, and it was well tolerated. In conclusion, subcutaneous evolocumab is a valuable new treatment for use in primary hypercholesterolemia or mixed dyslipidemia and homozygous familial hypercholesterolemia, particularly in patients unable to reach LDL-C goals despite treatment with statins with or without other lipid-lowering therapies and in patients who do not tolerate or are not able to receive statins.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 7, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.